Natera Inc shares reached a record $373.58 on Monday, surpassing the previous 52-week peak of $373.07. The milestone came after the company reported second-quarter revenue of approximately $753 million, exceeding Wall Street estimates of $661.26 million.
The stock gained 5.7% last week, extending a six-month advance of 89.8% and a one-year climb of 112.67%. Over the past twelve months, revenue grew 37.8%, driven by record volumes of its Signatera minimal residual disease test and a multi-cancer early detection screening assay.
Management cited improved margins and a series of regulatory approvals as reasons for raising full-year revenue guidance. Rothschild Redburn set a $385 price target, implying about 3% upside from current levels.
InvestingPro analysis noted the shares appear overvalued relative to its fair value estimate, while highlighting additional research tools available to subscribers.
